This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
blood donors | 1198 |
virus infection | 893 |
hcv infection | 865 |
blood transfusion | 853 |
chronic hepatitis | 848 |
hcv rna | 826 |
whole blood | 675 |
red blood | 616 |
immune response | 616 |
blood donation | 600 |
blood components | 579 |
virus replication | 560 |
study design | 552 |
rna replication | 537 |
core protein | 535 |
blood products | 532 |
blood group | 512 |
type i | 512 |
summary conclusions | 495 |
case studies | 490 |
viral replication | 487 |
red cell | 486 |
background case | 481 |
hcv replication | 475 |
infected cells | 468 |
antiviral activity | 455 |
hbv dna | 436 |
viral rna | 434 |
blood bank | 431 |
immune responses | 421 |
breast milk | 415 |
cell culture | 412 |
blood cells | 411 |
hcv ns | 406 |
gene expression | 405 |
viral load | 402 |
flow cytometry | 395 |
amino acid | 392 |
influenza virus | 389 |
design method | 387 |
liver disease | 383 |
results finding | 375 |
health care | 372 |
infected patients | 369 |
viral infections | 357 |
side effects | 357 |
innate immune | 354 |
transfusion medicine | 353 |
significantly higher | 350 |
dendritic cells | 341 |
cell lines | 340 |
hcv core | 331 |
immunodeficiency virus | 331 |
risk factors | 328 |
hepatocellular carcinoma | 327 |
human immunodeficiency | 327 |
infectious diseases | 327 |
blood donor | 326 |
peripheral blood | 325 |
rna viruses | 323 |
viral infection | 320 |
blood cell | 319 |
bone marrow | 318 |
host cell | 307 |
red cells | 307 |
united states | 304 |
nucleic acid | 304 |
mg kg | 303 |
adverse events | 300 |
cd cd | 295 |
virus type | 292 |
time pcr | 291 |
iu ml | 280 |
cell surface | 280 |
significant difference | 278 |
ng ml | 278 |
hiv infection | 277 |
control group | 275 |
viral proteins | 271 |
public health | 269 |
pregnant women | 267 |
cell line | 267 |
dengue virus | 265 |
transplant recipients | 263 |
class i | 261 |
liver transplantation | 259 |
virus entry | 258 |
life cycle | 256 |
abstract type | 255 |
please specify | 254 |
platelet concentrates | 253 |
clinical trials | 252 |
cell responses | 251 |
performed using | 247 |
transfusion reactions | 246 |
virus rna | 246 |
blood samples | 244 |
two groups | 242 |
immune system | 242 |
amino acids | 241 |
present study | 238 |
stem cell | 236 |
hbv infection | 234 |
hcv genotype | 231 |
mg ml | 230 |
mg dl | 226 |
rna polymerase | 222 |
statistically significant | 222 |
mean age | 219 |
west nile | 219 |
chronic hcv | 218 |
blood banks | 216 |
transfusion service | 214 |
herpes simplex | 214 |
hcv entry | 211 |
platelet count | 210 |
cell death | 209 |
respiratory syndrome | 208 |
cd cells | 205 |
specific cd | 205 |
host factors | 204 |
important role | 203 |
copies ml | 203 |
acute respiratory | 203 |
blood supply | 203 |
blood donations | 199 |
drug resistance | 198 |
nile virus | 194 |
cell proliferation | 189 |
blood collection | 189 |
simplex virus | 189 |
blood center | 188 |
blood units | 188 |
room temperature | 184 |
innate immunity | 183 |
endoplasmic reticulum | 183 |
virus ns | 182 |
severe acute | 182 |
quality control | 182 |
years old | 181 |
results suggest | 181 |
may also | 179 |
significant differences | 178 |
university hospital | 176 |
host cells | 176 |
outcome measures | 175 |
rna virus | 174 |
main outcome | 173 |
antiviral therapy | 173 |
cell activation | 172 |
cord uid | 171 |
doc id | 171 |
protein kinase | 169 |
adverse effects | 167 |
heat shock | 167 |
graft survival | 167 |
protein expression | 166 |
first time | 165 |
clinically significant | 165 |
high risk | 165 |
significantly lower | 164 |
monoclonal antibody | 163 |
blood safety | 163 |
patients treated | 163 |
one patient | 162 |
viral genome | 161 |
patients received | 161 |
like receptor | 160 |
infected individuals | 160 |
blood product | 159 |
viral protein | 157 |
intensive care | 157 |
stranded rna | 157 |
pg ml | 156 |
least one | 156 |
stem cells | 154 |
binding site | 154 |
plasma membrane | 153 |
rna synthesis | 152 |
membrane fusion | 152 |
abstract background | 152 |
combination therapy | 151 |
research abstract | 151 |
antiviral agents | 151 |
binding protein | 151 |
data suggest | 150 |
viral hepatitis | 149 |
protease inhibitors | 149 |
previously described | 148 |
i ifn | 148 |
epithelial cells | 147 |
mhc class | 146 |
liver fibrosis | 146 |
growth factor | 146 |
cell types | 146 |
patients receiving | 146 |
structural proteins | 145 |
dependent manner | 145 |
hcv replicon | 145 |
results indicate | 144 |
results findings | 144 |
increased risk | 143 |
mouse model | 143 |
cells expressing | 143 |
monoclonal antibodies | 142 |
infectious disease | 142 |
blood services | 141 |
determine whether | 141 |
strand rna | 139 |
western blot | 138 |
design methods | 138 |
bacterial contamination | 137 |
transfusion services | 136 |
liver cirrhosis | 135 |
patients undergoing | 135 |
virus core | 135 |
antiviral drugs | 135 |
staphylococcus aureus | 134 |
clinical practice | 134 |
specific antibodies | 133 |
rna interference | 133 |
hcv genotypes | 132 |
replication complex | 132 |
blood component | 132 |
chain reaction | 132 |
total number | 131 |
nucleic acids | 130 |
risk factor | 130 |
liver biopsy | 129 |
ex vivo | 129 |
liver transplant | 129 |
viral entry | 128 |
rbc units | 128 |
high levels | 127 |
significantly increased | 126 |
oxidative stress | 126 |
acute rejection | 126 |
expression levels | 125 |
class ii | 125 |
adaptive immune | 123 |
virus infections | 123 |
results show | 122 |
clinical trial | 121 |
reverse transcriptase | 121 |
national blood | 121 |
respiratory syncytial | 121 |
cell cycle | 121 |
huh cells | 121 |
shock protein | 120 |
transgenic mice | 120 |
wild type | 120 |
respiratory tract | 120 |
body weight | 120 |
fever virus | 119 |
long term | 119 |
blood centers | 119 |
polymerase chain | 119 |
antibody screening | 119 |
inhibitory effect | 119 |
transplant patients | 118 |
blood service | 118 |
renal transplant | 118 |
nonstructural protein | 118 |
recent years | 117 |
virus particles | 117 |
dependent rna | 116 |
donor selection | 116 |
high level | 116 |
drug use | 116 |
hcv genome | 115 |
cd expression | 115 |
syncytial virus | 115 |
autologous blood | 115 |
two different | 115 |
results showed | 115 |
antiglobulin test | 114 |
red cross | 114 |
medical center | 114 |
cytokine production | 113 |
blood pressure | 113 |
positive samples | 113 |
significantly reduced | 111 |
two patients | 111 |
well tolerated | 111 |
virus production | 111 |
previous studies | 111 |
mononuclear cells | 110 |
kidney transplant | 110 |
syndrome coronavirus | 110 |
platelet transfusion | 109 |
chronic liver | 109 |
adverse reactions | 108 |
positive results | 108 |
protease inhibitor | 108 |
blood loss | 108 |
ns protease | 108 |
care unit | 107 |
frozen plasma | 107 |
last years | 107 |
signaling pathways | 107 |
i interferon | 107 |
vaccinia virus | 107 |
general population | 106 |
nk cells | 105 |
positive patients | 105 |
molecular mechanisms | 105 |
patients infected | 104 |
hcv activity | 103 |
chronic infection | 103 |
er stress | 103 |
per year | 103 |
descriptive abstract | 103 |
among patients | 103 |
blood groups | 103 |
human papillomavirus | 103 |
rbc transfusion | 102 |
one case | 102 |
significant increase | 101 |
escherichia coli | 101 |
logistic regression | 101 |
statistical analysis | 101 |
transcription factor | 101 |
nonstructural proteins | 101 |
hcv infected | 100 |
hcv patients | 100 |
mammalian cells | 100 |
hcv infections | 99 |
signal transduction | 99 |
previously reported | 98 |
positive cells | 98 |
antiretroviral therapy | 98 |
hiv aids | 98 |
renal function | 98 |
year old | 98 |
nkt cells | 98 |
informed consent | 97 |
barr virus | 97 |
fresh frozen | 97 |
cord blood | 97 |
median age | 96 |
hcv treatment | 96 |
cell entry | 96 |
pegylated interferon | 95 |
liver failure | 95 |
also observed | 95 |
significant reduction | 95 |
factor viii | 94 |
encephalitis virus | 94 |
hepg cells | 94 |
healthy controls | 94 |
days post | 94 |
study period | 94 |
hcv proteins | 94 |
enveloped viruses | 94 |
host immune | 93 |
taken together | 93 |
analysis showed | 93 |
disease progression | 93 |
medication reconciliation | 93 |
nervous system | 92 |
ns protein | 92 |
hepatoma cells | 92 |
prospective study | 92 |
small molecule | 92 |
systematic review | 92 |
mass spectrometry | 92 |
cardiac surgery | 92 |
lipid droplets | 92 |
liver injury | 92 |
per patient | 91 |
rna genome | 91 |
serine protease | 91 |
animal models | 91 |
highly conserved | 91 |
type ii | 91 |
signaling pathway | 91 |
chronic viral | 90 |
virological response | 90 |
age group | 90 |
rna levels | 90 |
solid organ | 90 |
ebola virus | 90 |
cell transplantation | 90 |
novel coronavirus | 90 |
commercially available | 90 |
transfusion practice | 89 |
deficient mice | 89 |
drug users | 89 |
retrospective study | 89 |
acute hepatitis | 88 |
active site | 88 |
world health | 88 |
three times | 88 |
hla class | 88 |
sickle cell | 88 |
three patients | 88 |
blood volume | 88 |
large number | 88 |
japanese encephalitis | 87 |
viral loads | 87 |
inflammatory cytokines | 87 |
protein synthesis | 87 |
surface antigen | 87 |
even though | 87 |
viral particles | 87 |
antiviral effects | 87 |
described previously | 87 |
transfusion reaction | 86 |
organ transplantation | 86 |
like receptors | 86 |
virologic response | 86 |
ml min | 86 |
type iii | 86 |
cfu ml | 86 |
cell response | 86 |
neutralizing antibodies | 85 |
ifn response | 85 |
antibody screen | 85 |
protein levels | 85 |
may lead | 85 |
years ago | 85 |
renal failure | 85 |
general hospital | 85 |
reverse transcription | 84 |
yellow fever | 84 |
significantly different | 84 |
recent studies | 84 |
genome replication | 83 |
immune cells | 83 |
several studies | 83 |
retrospective analysis | 83 |
hematopoietic stem | 83 |
transfusion therapy | 83 |
also found | 83 |
alcohol use | 83 |
western blotting | 83 |
female donors | 83 |
dna polymerase | 83 |
target cells | 82 |
safe blood | 82 |
blood transfusions | 82 |
endothelial cells | 82 |
culture system | 82 |
time donors | 82 |
nitric oxide | 82 |
treated cells | 82 |
serum samples | 82 |
plasma samples | 81 |
cancer cells | 81 |
spectrum antiviral | 81 |
one year | 81 |
hcv particles | 81 |
unfolded protein | 81 |
protein response | 81 |
tlr signaling | 81 |
central nervous | 80 |
liver diseases | 80 |
significantly decreased | 80 |
closely related | 80 |
hcv screening | 80 |
study showed | 80 |
results obtained | 80 |
group system | 80 |
hepatoma cell | 80 |
patients without | 80 |
organ transplant | 80 |
cell transmission | 80 |
regression analysis | 80 |
human cells | 80 |
breast cancer | 79 |
cmv infection | 79 |
antiviral effect | 79 |
kidney transplantation | 79 |
chronically infected | 79 |
cars microscopy | 79 |
lipid metabolism | 79 |
presenting cells | 79 |
monoclonal anti | 79 |
massive transfusion | 79 |
new york | 79 |
cell receptor | 79 |
voluntary blood | 79 |
critical role | 79 |
replication complexes | 78 |
pathogen inactivation | 78 |
false positive | 78 |
results demonstrate | 78 |
clinical studies | 78 |
well plates | 78 |
patient care | 78 |
drug interactions | 78 |
antiviral response | 78 |
transcription factors | 78 |
health organization | 78 |
year period | 77 |
donate blood | 77 |
widely used | 77 |
luciferase activity | 77 |
million people | 77 |
envelope protein | 76 |
data indicate | 76 |
medication adherence | 76 |
real time | 76 |
molecular biology | 76 |
human hepatoma | 76 |
urinary tract | 76 |
cd cell | 76 |
human hepatocytes | 76 |
antigen presentation | 76 |
case report | 76 |
positive control | 76 |
healthy donors | 75 |
patient safety | 75 |
clinically relevant | 75 |
hla antibodies | 75 |
within days | 75 |
ifn production | 75 |
genomic dna | 75 |
within hours | 75 |
mrna expression | 75 |
kg day | 75 |
response rate | 75 |
expressing cells | 75 |
high prevalence | 75 |
phase i | 75 |
recent study | 74 |
blood banking | 74 |
fusion protein | 74 |
patient survival | 74 |
hemolytic transfusion | 74 |
meld score | 74 |
electron microscopy | 74 |
study group | 74 |
antibody identification | 74 |
entry site | 74 |
blot analysis | 73 |
health services | 73 |
expression level | 73 |
genomic rna | 73 |
viral clearance | 73 |
diabetes mellitus | 73 |
chronic hbv | 73 |
buffy coat | 73 |
hiv transmission | 72 |
envelope proteins | 72 |
donated blood | 72 |
donor screening | 72 |
wide range | 72 |
may contribute | 72 |
hcv ires | 72 |
direct antiglobulin | 72 |
autoimmune diseases | 71 |
high frequency | 71 |
lymph nodes | 71 |
hiv hcv | 71 |
graft function | 71 |
transfusion safety | 71 |
subgenomic replicon | 71 |
serum creatinine | 71 |
infectious virus | 71 |
viral life | 71 |
analyzed using | 71 |
vertical transmission | 71 |
internal medicine | 71 |
small interfering | 71 |
capsid protein | 71 |
surface expression | 71 |
tissue culture | 71 |
transfected cells | 71 |
results indicated | 71 |
blood mononuclear | 70 |
factors associated | 70 |
higher risk | 70 |
well known | 70 |
may occur | 70 |
mental health | 70 |
cellular proteins | 70 |
crystal structure | 69 |
serum hbv | 69 |
pathogen reduction | 69 |
serum levels | 69 |
cirrhotic patients | 69 |
cohort study | 69 |
dna levels | 69 |
response rates | 69 |
human cytomegalovirus | 69 |
predictive value | 69 |
ns helicase | 69 |
acting antiviral | 69 |
binding sites | 69 |
clinical pharmacist | 68 |
lncbst bispr | 68 |
mitochondrial dynamics | 68 |
hepatic fibrosis | 68 |
internal ribosome | 68 |
rhd gene | 68 |
dna viruses | 68 |
gene therapy | 68 |
antibiotic therapy | 68 |
viral dna | 68 |
infectious hcv | 68 |
inkt cells | 68 |
rna helicase | 68 |
plus ribavirin | 68 |
graft loss | 68 |
growth factors | 68 |
pilot study | 67 |
commonly used | 67 |
ribosome entry | 67 |
cell membrane | 67 |
iron deficiency | 67 |
serum alt | 67 |
five patients | 67 |
critically ill | 67 |
adaptive immunity | 67 |
window period | 67 |
alt levels | 67 |
family members | 67 |
antigen expression | 67 |
time points | 67 |
healthy volunteers | 67 |
disease virus | 66 |
host proteins | 66 |
molecular weight | 66 |
membrane vesicles | 66 |
measured using | 66 |
flow cytometric | 66 |
human cd | 66 |
liver tissue | 66 |
significant decrease | 66 |
low levels | 66 |
background aims | 66 |
first months | 66 |
cell count | 65 |
platelet counts | 65 |
cells infected | 65 |
may provide | 65 |
reading frame | 65 |
bacterial infections | 65 |
four patients | 65 |
antibody response | 65 |
clinical features | 65 |
disease control | 65 |
adult patients | 65 |
antiviral activities | 65 |
serious adverse | 65 |
treatment response | 65 |
renal transplantation | 65 |
resistance mutations | 65 |
antiviral drug | 65 |
chronic rejection | 64 |
viral diseases | 64 |
confirmed cases | 64 |
also showed | 64 |
statistical significance | 64 |
platelet products | 64 |
zika virus | 64 |
regulatory factor | 64 |
sustained virological | 64 |
positively selected | 64 |
log copies | 64 |
hsp inhibitors | 64 |
interferon alpha | 64 |
transfused patients | 64 |
first step | 64 |
three different | 64 |
key role | 64 |
terminal domain | 64 |
multivariate analysis | 64 |
infectious agents | 63 |
per day | 63 |
vesicular stomatitis | 63 |
increased expression | 63 |
generation sequencing | 63 |
chemokine receptor | 63 |
fold increase | 63 |
fatty liver | 63 |
dendritic cell | 63 |
per unit | 63 |
stimulated genes | 63 |
inflammatory response | 63 |
additive solution | 63 |
see table | 63 |
significantly associated | 63 |
authors declare | 63 |
virus detection | 62 |
infectious hepatitis | 62 |
antigen presenting | 62 |
influenza viruses | 62 |
standard deviation | 62 |
virus genotype | 62 |
mg day | 62 |
virus genome | 62 |
month period | 62 |
virus nonstructural | 62 |
clinical pharmacy | 62 |
treated patients | 62 |
immunocompromised patients | 62 |
virus assembly | 62 |
human milk | 62 |
i ifns | 62 |
severe disease | 61 |
buffy coats | 61 |
ferritin levels | 61 |
hepatitis virus | 61 |
positive donors | 61 |
natural killer | 61 |
stomatitis virus | 61 |
donor blood | 61 |
like particles | 61 |
insulin resistance | 61 |
findings suggest | 61 |
translation initiation | 61 |
complement activation | 61 |
i ii | 61 |
tract infection | 61 |
infected mice | 61 |
indirect antiglobulin | 61 |
may play | 61 |
primary human | 61 |
bact alert | 61 |
th cells | 61 |
mortality rate | 61 |
th day | 61 |
liver function | 61 |
health problem | 61 |
higher levels | 61 |
structural protein | 61 |
expressed breast | 61 |
rhce ce | 61 |
single nucleotide | 60 |
pcr assay | 60 |
total rna | 60 |
abo blood | 60 |
tumor cells | 60 |
lf cases | 60 |
quality assurance | 60 |
injection drug | 60 |
deficient cells | 60 |
drug discovery | 60 |
clinical use | 60 |
cell disease | 60 |
controlled trial | 60 |
major cause | 60 |
phase ii | 60 |
acting antivirals | 60 |
quantitative real | 60 |
months post | 60 |
negative control | 59 |
healthy individuals | 59 |
liver biopsies | 59 |
reference laboratory | 59 |
transfusion transmitted | 59 |
studies showed | 59 |
ion channel | 59 |
male donors | 59 |
clinical significance | 59 |
clinical data | 59 |
patients showed | 59 |
abstract withdrawn | 59 |
also known | 59 |
rna pol | 58 |
two cases | 58 |
six months | 58 |
human liver | 58 |
open reading | 58 |
transmitted infections | 58 |
replication cycle | 58 |
protein interactions | 58 |
envelope glycoproteins | 58 |
high throughput | 58 |
high dose | 58 |
storage time | 58 |
test results | 58 |
preliminary results | 58 |
sars coronavirus | 58 |
plasma units | 58 |
analysis revealed | 58 |
hemorrhagic fever | 58 |
apheresis platelets | 58 |
control cells | 58 |
lipid rafts | 58 |
ns proteins | 58 |
survival rates | 58 |
cd foxp | 58 |
tract infections | 57 |
survival rate | 57 |
binding proteins | 57 |
culture media | 57 |
may result | 57 |
mast cells | 57 |
i molecules | 57 |
elderly patients | 57 |
study shows | 57 |
data collection | 57 |
cell lysates | 57 |
highly sensitive | 57 |
necrosis factor | 57 |
negative blood | 57 |
allograft rejection | 57 |
premature infants | 57 |
may cause | 57 |
virus life | 57 |
ifn therapy | 57 |
drug development | 57 |
tested positive | 57 |
much higher | 57 |
cell differentiation | 57 |
using two | 57 |
blood type | 57 |
immune evasion | 56 |
liver cancer | 56 |
platelets stored | 56 |
cell cultures | 56 |
regional blood | 56 |
coding region | 56 |
blood management | 56 |
positive selection | 56 |
specific immune | 56 |
column agglutination | 56 |
two years | 56 |
will also | 56 |
young children | 56 |
plasmacytoid dendritic | 56 |
hb level | 56 |
naturally occurring | 56 |
healthy subjects | 55 |
primary care | 55 |
ko mice | 55 |
animal model | 55 |
cell subsets | 55 |
broad spectrum | 55 |
clinical outcome | 55 |
six patients | 55 |
quality management | 55 |
scavenger receptor | 55 |
hospital transfusion | 55 |
small number | 55 |
united kingdom | 55 |
hcv viral | 55 |
hours post | 55 |
antiviral treatment | 55 |
lg ml | 55 |
chb patients | 55 |
inhibit hcv | 55 |
confirmed lf | 54 |
determined using | 54 |
reporter gene | 54 |
scansystem tm | 54 |
units per | 54 |
inhibitory effects | 54 |
information system | 54 |
gene silencing | 54 |
coding sequence | 54 |
hemolytic anemia | 54 |
hospitalized patients | 54 |
cells treated | 54 |
streptococcus pneumoniae | 54 |
bacterial infection | 54 |
ns activated | 54 |
host factor | 54 |
repeat donors | 54 |
similar results | 54 |
interfering rna | 54 |
positive result | 54 |
may represent | 54 |
specific primers | 54 |
effective treatment | 54 |
nk cell | 54 |
suspected cases | 54 |
inclusion criteria | 53 |
activated protein | 53 |
white blood | 53 |
current study | 53 |
blood sample | 53 |
ml kg | 53 |
rare blood | 53 |
one month | 53 |
detection limit | 53 |
hcv hiv | 53 |
mediated rejection | 53 |
nucleocapsid protein | 53 |
donor age | 53 |
untranslated region | 53 |
sequence analysis | 53 |
avian influenza | 53 |
luciferase reporter | 53 |
national health | 53 |
cell viability | 53 |
medical records | 53 |
plasma exchange | 53 |
platelet transfusions | 53 |
therapeutic potential | 53 |
blood centre | 53 |
two weeks | 52 |
hiv positive | 52 |
clinical symptoms | 52 |
positive dat | 52 |
allogeneic blood | 52 |
may help | 52 |
highly effective | 52 |
specific antibody | 52 |
bl mice | 52 |
conformational changes | 52 |
abo rh | 52 |
er membrane | 52 |
trauma patients | 52 |
study aimed | 52 |
patient blood | 52 |
observational study | 52 |
european countries | 52 |
inject drugs | 52 |
blood cultures | 52 |
fully automated | 51 |
negative patients | 51 |
screening test | 51 |
trima accel | 51 |
mrna levels | 51 |
inhibitory activity | 51 |
hcv protein | 51 |
body mass | 51 |
cell concentrates | 51 |
also tested | 51 |
blood screening | 51 |
clinical outcomes | 51 |
previous study | 51 |
cervical cancer | 51 |
donor population | 51 |
interferon regulatory | 51 |
hemolytic disease | 51 |
membranous web | 51 |
age years | 50 |
liver cells | 50 |
donor samples | 50 |
hcv antibody | 50 |
apoptotic cells | 50 |
low level | 50 |
hubei province | 50 |
vg vd | 50 |
ill patients | 50 |
flaviviridae family | 50 |
packed red | 50 |
pi kiii | 50 |
high incidence | 50 |
group antigens | 50 |
rna binding | 50 |
significant effect | 50 |
cancer patients | 50 |
fetal dna | 50 |
treated rbcs | 50 |
blood system | 50 |
adaptor protein | 50 |
channel activity | 50 |
culture systems | 50 |
blood flow | 50 |
plt count | 50 |
sustained virologic | 50 |
pneumoniae isolates | 50 |
lupus erythematosus | 50 |
acid residues | 50 |
hiv co | 50 |
tumor necrosis | 50 |
pcr amplification | 49 |
viral response | 49 |
birth weight | 49 |
currently available | 49 |
medical record | 49 |
virus envelope | 49 |
density lipoprotein | 49 |
included patients | 49 |
mediated translation | 49 |
bacterial pneumonia | 49 |
replicon cells | 49 |
low hb | 49 |
natural history | 49 |
acid sequence | 49 |
protective effect | 49 |
eight patients | 49 |
cell units | 49 |
cell populations | 49 |
cardiovascular disease | 49 |
serum albumin | 49 |
supplementary material | 49 |
apheresis platelet | 49 |
molecular methods | 49 |
three months | 49 |
entry factors | 49 |
data show | 49 |
dna level | 49 |
bovine serum | 49 |
storage period | 49 |
cells transfected | 49 |
viral genomes | 49 |
terminal region | 49 |
age groups | 49 |
hcv polymerase | 49 |
lung injury | 49 |
emergency department | 49 |
infection control | 49 |
hbeag negative | 48 |
quantitative pcr | 48 |
zoster virus | 48 |
innate antiviral | 48 |
portal hypertension | 48 |
disease severity | 48 |
ifn signaling | 48 |
human coronavirus | 48 |
systemic lupus | 48 |
reactive oxygen | 48 |
investigated whether | 48 |
one week | 48 |
hcv life | 48 |
blood establishments | 48 |
membrane protein | 48 |
final concentration | 48 |
also used | 48 |
cell transfusion | 48 |
time period | 48 |
cell epitopes | 48 |
i production | 48 |
high affinity | 48 |
crucial role | 48 |
platelet units | 48 |
recognition receptors | 48 |
different types | 47 |
adverse event | 47 |
clinical isolates | 47 |
also performed | 47 |
tested using | 47 |
gel test | 47 |
klebsiella pneumoniae | 47 |
hcc patients | 47 |
also reported | 47 |
type diabetes | 47 |
interferon signaling | 47 |
evaluated using | 47 |
treatment options | 47 |
peginterferon alfa | 47 |
based assays | 47 |
high sensitivity | 47 |
data analysis | 47 |
alanine aminotransferase | 47 |
treatment failure | 47 |
rhd negative | 47 |
gel electrophoresis | 47 |
developing countries | 47 |
mitochondrial fission | 47 |
post transfusion | 47 |
data collected | 47 |
one hundred | 47 |
rbc transfusions | 47 |
allograft survival | 47 |
substance use | 47 |
medical university | 47 |
phylogenetic analysis | 47 |
infection may | 47 |
early stage | 47 |
molecular basis | 46 |
hcv subgenomic | 46 |
mass index | 46 |
viral rnas | 46 |
among blood | 46 |
remains unclear | 46 |
mortality rates | 46 |
bacterial growth | 46 |
patient population | 46 |
center background | 46 |
ms ms | 46 |
persistent infection | 46 |
cd molecules | 46 |
cellular factors | 46 |
effector cells | 46 |
single donor | 46 |
complement system | 46 |
platelet function | 46 |
positive donations | 46 |
confidence interval | 46 |
recently reported | 46 |
young people | 46 |
analysis using | 46 |
health status | 46 |
essential role | 46 |
fusion proteins | 46 |
treated mice | 46 |
interfering rnas | 46 |
three groups | 46 |
nuclear translocation | 46 |
significant antibodies | 46 |
rhd genotyping | 46 |
middle east | 46 |
antibody responses | 46 |
arachidonic acid | 45 |
infection among | 45 |
capsid proteins | 45 |
human hepatitis | 45 |
bile duct | 45 |
serum ferritin | 45 |
nuclear import | 45 |
cell development | 45 |
target dna | 45 |
hiv replication | 45 |
lamp assay | 45 |
antiviral therapies | 45 |
antiviral compounds | 45 |
helicase activity | 45 |
randomized controlled | 45 |
assessed using | 45 |
cell counts | 45 |
therapeutic plasma | 45 |
patients suffering | 45 |
potent anti | 45 |
rna aptamers | 45 |
oxygen species | 45 |
host interactions | 45 |
nucleoside analogues | 45 |
will provide | 45 |
antiviral responses | 45 |
vitro studies | 45 |
reperfusion injury | 45 |
multiple sclerosis | 45 |
lassa fever | 44 |
relatively high | 44 |
primary infection | 44 |
general practitioners | 44 |
times higher | 44 |
platelet storage | 44 |
hcv therapy | 44 |
platelet antigens | 44 |
high titer | 44 |
leading cause | 44 |
hbc positive | 44 |
ec values | 44 |
iron stores | 44 |
stellate cells | 44 |
hcv positive | 44 |
old female | 44 |
rna molecules | 44 |
hcv antibodies | 44 |
new antiviral | 44 |
day post | 44 |
terumo bct | 44 |
low risk | 44 |
will help | 44 |
platelet pools | 44 |
clinical samples | 44 |
independent experiments | 44 |
blood grouping | 44 |
solid phase | 44 |
treatment duration | 44 |
core antigen | 44 |
induced apoptosis | 44 |
cell growth | 44 |
study also | 44 |
hospital stay | 44 |
many viruses | 44 |
antiviral signaling | 44 |
atpase activity | 44 |
cell function | 43 |
pediatric patients | 43 |
shock proteins | 43 |
using anti | 43 |
cells may | 43 |
particle production | 43 |
patient received | 43 |
hbv replication | 43 |
poorly understood | 43 |
rna helicases | 43 |
binding domain | 43 |
graft failure | 43 |
confocal microscopy | 43 |
study included | 43 |
routine use | 43 |
liver damage | 43 |
adoptive transfer | 43 |
management system | 43 |
rich plasma | 43 |
iron depletion | 43 |
subcellular localization | 43 |
resistant staphylococcus | 43 |
plasma levels | 43 |
harm reduction | 43 |
genetic diversity | 43 |
fluorescence microscopy | 43 |
human plasma | 43 |
common cause | 43 |
iron supplementation | 43 |
antiviral agent | 43 |
positive antibody | 43 |
hcv envelope | 42 |
first year | 42 |
clinical development | 42 |
myocardial infarction | 42 |
russian federation | 42 |
cell population | 42 |
sars cov | 42 |
cells using | 42 |
time blood | 42 |
stress response | 42 |
complex formation | 42 |
significant changes | 42 |
laboratory tests | 42 |
clinical study | 42 |
cells via | 42 |
activated mazf | 42 |
viral pathogenesis | 42 |
older adults | 42 |
hb levels | 42 |
may affect | 42 |
hong kong | 42 |
future studies | 42 |
swine fever | 42 |
alcohol consumption | 42 |
medical staff | 42 |
laboratory testing | 42 |
escape mutants | 42 |
smooth muscle | 42 |
nucleotide sequence | 42 |
three years | 42 |
antibody tests | 42 |
interferon alfa | 42 |
sectional study | 42 |
resistant strains | 42 |
investigate whether | 42 |
resistant mutants | 42 |
table shows | 42 |
inhibits hepatitis | 42 |
care units | 42 |
important cause | 41 |
cmv disease | 41 |
based assay | 41 |
producing cells | 41 |
highly active | 41 |
linear regression | 41 |
isg expression | 41 |
teaching hospital | 41 |
old male | 41 |
heart failure | 41 |
platelet concentrate | 41 |
effector functions | 41 |
rna positive | 41 |
platelet yield | 41 |
mycophenolate mofetil | 41 |
ribavirin therapy | 41 |
fatty acid | 41 |
protease activity | 41 |
induction therapy | 41 |
chronic disease | 41 |
cell clones | 41 |
transfusion center | 41 |
small molecules | 41 |
potent antiviral | 41 |
twice daily | 41 |
measles virus | 41 |
two major | 41 |
inhibited hcv | 41 |
endemic areas | 41 |
hbeag positive | 41 |
reticulum stress | 41 |
related problems | 41 |
stage liver | 41 |
hbeag seroconversion | 41 |
pattern recognition | 41 |
donor recruitment | 41 |
cellular immune | 41 |
past years | 41 |
african american | 41 |
seven patients | 41 |
human origin | 41 |
human serum | 40 |
antibiotic resistance | 40 |
clinical pharmacists | 40 |
cell survival | 40 |
soft tissue | 40 |
inhibits hcv | 40 |
two distinct | 40 |
aged years | 40 |
raman scattering | 40 |
receptor complex | 40 |
virus cell | 40 |
alloimmune thrombocytopenia | 40 |
upper respiratory | 40 |
proinflammatory cytokines | 40 |
cellular processes | 40 |
quality system | 40 |
high quality | 40 |
direct contact | 40 |
control mice | 40 |
cell antigens | 40 |
mycobacterium tuberculosis | 40 |
via breast | 40 |
post transplant | 40 |
single dose | 40 |
clinical characteristics | 40 |
host disease | 40 |
previously shown | 40 |
selected sites | 40 |
mean value | 40 |
different cell | 40 |
core expression | 40 |
viral envelope | 40 |
vitro selection | 40 |
least two | 40 |
increased significantly | 40 |
infected cell | 40 |
chikungunya virus | 40 |
medical care | 40 |
clinical signs | 40 |
related complications | 40 |
pharmaceutical care | 40 |
high rate | 39 |
puerto rico | 39 |
microarray analysis | 39 |
infectious particles | 39 |
different stages | 39 |
genes involved | 39 |
type mice | 39 |
viral particle | 39 |
protein translation | 39 |
negative bacteria | 39 |
significant correlation | 39 |
high viral | 39 |
renal allograft | 39 |
odds ratio | 39 |
patients may | 39 |
positive rate | 39 |
target cell | 39 |
particle assembly | 39 |
cells showed | 39 |
acute hcv | 39 |
nuclear localization | 39 |
oral administration | 39 |
cucs nanocomposite | 39 |
igg antibodies | 39 |
per month | 39 |
probably due | 39 |
free survival | 39 |
sanger sequencing | 39 |
biological activity | 39 |
hcv cell | 39 |
anti hpa | 39 |
negative controls | 39 |
virus proteins | 39 |
denv infection | 39 |
human herpesvirus | 39 |
drug therapy | 39 |
clinical manifestations | 39 |
transfusion practices | 39 |
core gene | 39 |
assay using | 39 |
cleavage sites | 39 |
inflammatory cytokine | 39 |
viral capsid | 39 |
allergic reactions | 39 |
heterogeneous nuclear | 39 |
transfusion related | 39 |
two days | 39 |
poster sessions | 39 |
living donor | 39 |
acute lung | 39 |
tyrosine kinase | 39 |
average age | 39 |
chv ns | 38 |
reported cases | 38 |
body fluids | 38 |
expressing ewi | 38 |
clinical course | 38 |
risk patients | 38 |
analysed using | 38 |
goat anti | 38 |
platelet quality | 38 |
czech republic | 38 |
clinical relevance | 38 |
increasing number | 38 |
fluorescence intensity | 38 |
tlr agonists | 38 |
antibody titers | 38 |
patients underwent | 38 |
developed countries | 38 |
control samples | 38 |
five years | 38 |
pregnant woman | 38 |
done using | 38 |
influenza infection | 38 |
better understanding | 38 |
envelope glycoprotein | 38 |
host response | 38 |
first report | 38 |
well documented | 38 |
care system | 38 |
subgenomic replicons | 38 |
detected using | 38 |
tumor cell | 38 |
common cold | 38 |
pivotal role | 38 |
global health | 38 |
clinical response | 38 |
renal disease | 38 |
showed significant | 38 |
length hcv | 38 |
studies suggest | 38 |
plus strand | 38 |
retrospective review | 38 |
waiting list | 38 |
human genome | 38 |
next generation | 38 |
transfusion associated | 38 |
hospital blood | 38 |
weight loss | 38 |
treg cells | 38 |
may explain | 38 |
randomly selected | 38 |
applied biosystems | 38 |
potential role | 38 |
another study | 38 |
fatty acids | 38 |
major role | 38 |
host innate | 38 |
medical history | 38 |
hepatic failure | 37 |
neonatal alloimmune | 37 |
cell separator | 37 |
samples collected | 37 |
lower respiratory | 37 |
secondary structure | 37 |
potential risk | 37 |
significant improvement | 37 |
virus hepatitis | 37 |
hcv transmission | 37 |
control study | 37 |
negative results | 37 |
wnv infection | 37 |
close contact | 37 |
median time | 37 |
cobe spectra | 37 |
interferon lambda | 37 |
haemolytic disease | 37 |
mainland china | 37 |
nuclear factor | 37 |
year survival | 37 |
platelet concentration | 37 |
university school | 37 |
evidence suggests | 37 |
transfusion recipients | 37 |
higher prevalence | 37 |
child transmission | 37 |
respiratory viruses | 37 |
gamma globulin | 37 |
severe thrombocytopenia | 37 |
polymerase inhibitors | 37 |
university medical | 37 |
inflammatory responses | 37 |
causative agent | 37 |
ethnic groups | 37 |
broad range | 37 |
patients included | 37 |
firefly luciferase | 37 |
cytomegalovirus infection | 37 |
replicon rna | 37 |
high degree | 37 |
studies show | 37 |
acute viral | 37 |
acid sequences | 37 |
total bilirubin | 37 |
relatively low | 37 |
allowed us | 37 |
coagulation factors | 37 |
study demonstrates | 37 |
advisory committee | 37 |
drug resistant | 37 |
therapeutic target | 37 |
patient samples | 37 |
lower levels | 37 |
plasma cells | 37 |
molecule inhibitors | 37 |
enzyme immunoassay | 37 |
mean number | 37 |
recombinant human | 37 |
compatible blood | 37 |
bacterial screening | 37 |
adverse reaction | 37 |
enzyme treated | 37 |
dna replication | 37 |
immune complexes | 37 |
national institute | 37 |
replicon system | 37 |
health professionals | 37 |
viral inactivation | 36 |
cell type | 36 |
ifn treatment | 36 |
virus release | 36 |
tm platelet | 36 |
lt recipients | 36 |
mice showed | 36 |
drug design | 36 |
lipid droplet | 36 |
knockout mice | 36 |
therapeutic agents | 36 |
one study | 36 |
corrective actions | 36 |
ns serine | 36 |
donating blood | 36 |
oral bioavailability | 36 |
american red | 36 |
mutation rate | 36 |
residual risk | 36 |
inflammatory diseases | 36 |
selection criteria | 36 |
acid testing | 36 |
enzymatic activity | 36 |
using flow | 36 |
information security | 36 |
immunosorbent assay | 36 |
acute infection | 36 |
receptor expression | 36 |
potential therapeutic | 36 |
cov helicase | 36 |
data demonstrate | 36 |
transmission via | 36 |
incubation period | 36 |
three days | 36 |
associated protein | 36 |
sexually transmitted | 36 |
apheresis procedures | 36 |
sense rna | 36 |
group systems | 36 |
patients aged | 36 |
tertiary care | 36 |
significantly correlated | 36 |
virus genotypes | 36 |
positive blood | 36 |
fibrosis stage | 36 |
oxide synthase | 36 |
health insurance | 36 |
many patients | 36 |
facs analysis | 36 |
hiv rna | 36 |
kidney disease | 36 |
host protein | 36 |
hcv protease | 36 |
resistant virus | 36 |
gold standard | 36 |
platelet kit | 36 |
membrane alterations | 36 |
alpha interferon | 36 |
per well | 36 |
kindly provided | 36 |
among others | 36 |
mice treated | 36 |
related mortality | 35 |
daa treatment | 35 |
two independent | 35 |
breastfed infants | 35 |
hcv clearance | 35 |
care providers | 35 |
acute phase | 35 |
rhd positive | 35 |
i interferons | 35 |
data obtained | 35 |
respiratory disease | 35 |
well established | 35 |
mouth disease | 35 |
i responses | 35 |
genotype patients | 35 |
amantadine sulphate | 35 |
immunosuppressive therapy | 35 |
months later | 35 |
polypyrimidine tract | 35 |
take place | 35 |
new insights | 35 |
blood culture | 35 |
proteins involved | 35 |
entry inhibitors | 35 |
rna silencing | 35 |
bacterial detection | 35 |
liver graft | 35 |
drug administration | 35 |
hepatic stellate | 35 |
human peripheral | 35 |
cd ko | 35 |
extremely rare | 35 |
may serve | 35 |
interferon response | 35 |
nine patients | 35 |
clinical setting | 35 |
recent data | 35 |
culture medium | 35 |
donor base | 35 |
treatment regimens | 35 |
ifnl snps | 35 |
treated animals | 35 |
genotype infection | 35 |
donor cells | 35 |
mean hb | 35 |
antiviral immunity | 35 |
clinical impact | 35 |
nuclear ribonucleoprotein | 35 |
risk reduction | 35 |
high rates | 35 |
urgent need | 35 |
results demonstrated | 35 |
pam cys | 35 |
different hcv | 35 |
polymerase activity | 35 |
virion assembly | 35 |
screening tests | 35 |
hcv co | 35 |
susceptibility testing | 35 |
throughput screening | 34 |
health service | 34 |
genetic barrier | 34 |
culture models | 34 |
adefovir dipivoxil | 34 |
community pharmacy | 34 |
antiviral efficacy | 34 |
physical examination | 34 |
wt mice | 34 |
first line | 34 |
alkaline phosphatase | 34 |
therapeutic strategies | 34 |
adverse drug | 34 |
mean platelet | 34 |
lymph node | 34 |
increasing concentrations | 34 |
central role | 34 |
weeks later | 34 |
nucleoside analogs | 34 |
new donors | 34 |
ciency virus | 34 |
hiv viral | 34 |
human blood | 34 |
drug related | 34 |
sindbis virus | 34 |
mechanisms underlying | 34 |
transmembrane domain | 34 |
interstitial pneumonitis | 34 |
early detection | 34 |
drug delivery | 34 |
different blood | 34 |
using different | 34 |
significantly less | 34 |
plasma fractionation | 34 |
virus dna | 34 |
mouse hepatitis | 34 |
health promotion | 34 |
cultured cells | 34 |
cleavage site | 34 |
stimulated gene | 34 |
days later | 34 |
fluorescent protein | 34 |
pseudomonas aeruginosa | 34 |
protective immunity | 34 |
neonatal intensive | 34 |
group i | 34 |
significantly improved | 34 |
respiratory distress | 34 |
mop aads | 34 |
herpes virus | 34 |
science foundation | 34 |
significant association | 34 |
viral disease | 34 |
also shown | 34 |
dna virus | 34 |
pneumocystis jirovecii | 34 |
forming units | 34 |
normal range | 34 |
vitro activity | 34 |
ischemia reperfusion | 34 |
standard operating | 34 |
hcv helicase | 34 |
cells per | 34 |
also evaluated | 34 |
viral persistence | 34 |
hepatitis delta | 34 |
cerebrospinal fluid | 34 |
antibody detection | 34 |
antibodies directed | 34 |
clinical efficacy | 34 |
genome sequence | 34 |
vitro quality | 34 |
protein ns | 34 |
serological testing | 34 |
findings indicate | 34 |
receptor binding | 34 |
fungal infections | 34 |
viral pathogens | 34 |
medical treatment | 33 |
human pathogens | 33 |
confirmed positive | 33 |
acute liver | 33 |
well understood | 33 |
molecular mechanism | 33 |
overall survival | 33 |
normal rhd | 33 |
scd patients | 33 |
steady state | 33 |
influenza vaccine | 33 |
large numbers | 33 |
heart disease | 33 |
severe sepsis | 33 |
may reflect | 33 |
reagent lots | 33 |
african americans | 33 |
rna translation | 33 |
mouse models | 33 |
decompensated cirrhosis | 33 |
folic acid | 33 |
three independent | 33 |
antiviral properties | 33 |
pcr products | 33 |
three cases | 33 |
electronic medical | 33 |
newly synthesized | 33 |
last year | 33 |
specific inhibitors | 33 |
hepatitis viruses | 33 |
cells well | 33 |
chronic allograft | 33 |
research institute | 33 |
last decade | 33 |
low dose | 33 |
negative strand | 33 |
dependent translation | 33 |
specific anti | 33 |
injecting drug | 33 |
increased susceptibility | 33 |
serum hcv | 33 |
patients compared | 33 |
also determined | 33 |
mm tris | 33 |
preliminary data | 33 |
samples obtained | 33 |
negative suspected | 33 |
membrane structures | 33 |
units transfused | 33 |
sample size | 33 |
luciferase assay | 33 |
semliki forest | 33 |
virus transmission | 33 |
diarrhea virus | 33 |
two types | 33 |
wide variety | 33 |
adoptively transferred | 33 |
medicinal chemistry | 33 |
highly variable | 33 |
drug sharing | 33 |
among people | 33 |
low ph | 33 |
mast cell | 33 |
renilla luciferase | 33 |
acid substitutions | 33 |
study suggests | 33 |
old woman | 33 |
bovine viral | 33 |
risk groups | 33 |
htlv i | 32 |
shelf life | 32 |
entry factor | 32 |
membrane proteins | 32 |
protein interaction | 32 |
drug targets | 32 |
cross blood | 32 |
coinfected patients | 32 |
antiviral research | 32 |
multidisciplinary team | 32 |
will discuss | 32 |
antibody mediated | 32 |
hydrogen bond | 32 |
tested negative | 32 |
reporter system | 32 |
immunode fi | 32 |
lung transplantation | 32 |
south africa | 32 |
mouse monoclonal | 32 |
ccr expression | 32 |
better understand | 32 |
stranded dna | 32 |
uncleavable mazf | 32 |
analytical sensitivity | 32 |
multiple myeloma | 32 |
short period | 32 |
lt patients | 32 |
igm antibodies | 32 |
disease prevention | 32 |
gestational age | 32 |
antimicrobial therapy | 32 |
risk assessment | 32 |
time point | 32 |
ml per | 32 |
working group | 32 |
likely due | 32 |
patients developed | 32 |
will allow | 32 |
mitochondrial membrane | 32 |
samples tested | 32 |
initiation factor | 32 |
studies using | 32 |
forest virus | 32 |
resistance gene | 32 |
randomized trial | 32 |
inflammatory bowel | 32 |
regular blood | 32 |
two samples | 32 |
promoter activity | 32 |
also demonstrated | 32 |
apoptotic cell | 32 |
first days | 32 |
infected hepatocytes | 32 |
hcv replicons | 32 |
platelet refractoriness | 32 |
viral infectivity | 32 |
also significantly | 32 |
active antiretroviral | 32 |
pcr assays | 32 |
bacterial meningitis | 32 |
fi ciency | 32 |
patient groups | 32 |
molecular testing | 32 |
obtained using | 32 |
polyclonal anti | 32 |
hpa antibodies | 32 |
related acute | 31 |
host defense | 31 |
assay system | 31 |
respiratory illness | 31 |
dna positive | 31 |
several years | 31 |
patients experienced | 31 |
cell therapy | 31 |
drug treatment | 31 |
also analyzed | 31 |
new class | 31 |
presentation will | 31 |
low frequency | 31 |
also associated | 31 |
deferred donors | 31 |
cbvct services | 31 |
lymphocytic choriomeningitis | 31 |
tlr agonist | 31 |
relative risk | 31 |
hiv disease | 31 |
liver inflammation | 31 |
orthotopic liver | 31 |
blood collected | 31 |
iii ifns | 31 |
long time | 31 |
average number | 31 |
nucleotide polymorphisms | 31 |
also included | 31 |
antibiotic treatment | 31 |
receptor class | 31 |
detection methods | 31 |
increased levels | 31 |
patients using | 31 |
abdominal pain | 31 |
one hour | 31 |
leukemia virus | 31 |
examine whether | 31 |
many cases | 31 |
study will | 31 |
stress proteins | 31 |
interferon therapy | 31 |
actin cytoskeleton | 31 |
nkt cell | 31 |
mediated cleavage | 31 |
hpv infection | 31 |
decreased significantly | 31 |
pcr analysis | 31 |
replicase complex | 31 |
much lower | 31 |
nursing home | 31 |
septic shock | 31 |
controlled trials | 31 |
cold storage | 31 |
one unit | 31 |
mg daily | 31 |
inducible nitric | 31 |
cell signaling | 31 |
significant role | 31 |
different viruses | 31 |
cell leukemia | 31 |
group ii | 31 |
screening assays | 31 |
consecutive patients | 31 |
acute renal | 31 |
ethyl acetate | 31 |
limited number | 31 |
among hiv | 31 |
within months | 31 |
also examined | 31 |
genetic material | 31 |
term follow | 31 |
infected subjects | 31 |
dna sequencing | 31 |
blood bags | 31 |
differentially expressed | 31 |
provide evidence | 31 |
ntat aneo | 31 |
virus strains | 31 |
dna samples | 31 |
infection hepatitis | 31 |
serologic testing | 31 |
tube method | 31 |
resistant viruses | 31 |
therapeutic effect | 31 |
new therapeutic | 31 |
protein level | 31 |
negative individuals | 31 |
cd count | 30 |
mechanisms involved | 30 |
sinusoidal endothelial | 30 |
clinical applications | 30 |
many countries | 30 |
may act | 30 |
control groups | 30 |
viral gene | 30 |
agglutination technology | 30 |
patients admitted | 30 |
signaling protein | 30 |
also increased | 30 |
negative regulator | 30 |
surgical procedures | 30 |
significantly elevated | 30 |
currently used | 30 |
per week | 30 |
different mechanisms | 30 |
alcohol intake | 30 |
cellular rejection | 30 |
detection system | 30 |
stat signaling | 30 |
repeat blood | 30 |
new blood | 30 |
study conducted | 30 |
case study | 30 |
healthcare professionals | 30 |
serologic tests | 30 |
graft rejection | 30 |
clinical status | 30 |
reagent red | 30 |
beneficial effect | 30 |
deleterious effects | 30 |
male patients | 30 |
among different | 30 |
chronic inflammatory | 30 |
rna polymerases | 30 |
replacement therapy | 30 |
donor center | 30 |
cells ml | 30 |
safety profile | 30 |
gold nanoparticles | 30 |
therapeutic targets | 30 |
inventory management | 30 |
viral diarrhea | 30 |
viral polymerase | 30 |
information regarding | 30 |
independent risk | 30 |
protein degradation | 30 |
platelet components | 30 |
serial dilutions | 30 |
antibody positive | 30 |
phase iii | 30 |
different time | 30 |
may induce | 30 |
ebv infection | 30 |
th cytokines | 30 |
agar dilution | 30 |
fold higher | 30 |
hcv prevalence | 30 |
infected persons | 30 |
statistical difference | 30 |
term survival | 30 |
acid amplification | 30 |
ic values | 30 |
also detected | 30 |
transfusion protocol | 30 |
recent advances | 30 |
different countries | 30 |
higher rates | 30 |
patient identification | 30 |
hematopoietic cells | 30 |
combination treatment | 30 |
fusion peptide | 30 |
cell migration | 30 |
vaccine development | 30 |
antiviral strategies | 30 |
life technologies | 30 |
direct acting | 30 |
regular donors | 29 |
viral ns | 29 |
flow cytometer | 29 |
dna load | 29 |
competing interests | 29 |
total protein | 29 |
large amounts | 29 |
based therapy | 29 |
vast majority | 29 |
hcv nonstructural | 29 |
viral proteases | 29 |
fda approved | 29 |
transfusion vol | 29 |
potent inhibitor | 29 |
linked immunosorbent | 29 |
natural science | 29 |
human platelet | 29 |
study demonstrated | 29 |
lipoprotein receptor | 29 |
spontaneous clearance | 29 |
antigen processing | 29 |
antibody testing | 29 |
study aims | 29 |
urban health | 29 |
improve patient | 29 |
lung cancer | 29 |
cellular membranes | 29 |
adhesion molecule | 29 |
human viruses | 29 |
last months | 29 |
standard therapy | 29 |
mean serum | 29 |
tumor suppressor | 29 |
family flaviviridae | 29 |
recent reports | 29 |
takes place | 29 |
study population | 29 |
positive correlation | 29 |
genetic variation | 29 |
plasma products | 29 |
molecular techniques | 29 |
adverse effect | 29 |
first two | 29 |
specific inhibitor | 29 |
patients died | 29 |
cells harboring | 29 |
inducible gene | 29 |
decision making | 29 |
selective pressure | 29 |
log iu | 29 |
group antigen | 29 |
direct interaction | 29 |
therapeutic approach | 29 |
factors involved | 29 |
viral protease | 29 |
svr rates | 29 |
urban areas | 29 |
vero cells | 29 |
bk virus | 29 |
circulatory overload | 29 |
mediated isothermal | 29 |
rbc antigens | 29 |
cd positive | 29 |
major challenge | 29 |
operating procedures | 29 |
two methods | 29 |
respiratory failure | 29 |
cd deficiency | 29 |
standard methods | 29 |
surface area | 29 |
human respiratory | 29 |
sexual partners | 29 |
patients presented | 29 |
matrix protein | 29 |
abo typing | 29 |
time quantitative | 29 |
induced liver | 29 |
choriomeningitis virus | 29 |
cell antibodies | 29 |
uninfected cells | 29 |
strains isolated | 29 |
blood derived | 29 |
herpes zoster | 29 |
nat screening | 29 |
treated rats | 29 |
human health | 29 |
high school | 29 |
may reduce | 29 |
platelet aggregation | 29 |
intravenous drug | 29 |
bleeding patients | 28 |
type virus | 28 |
less likely | 28 |
manual tube | 28 |
viral attachment | 28 |
progenitor cells | 28 |
listeria monocytogenes | 28 |
delta virus | 28 |
living cells | 28 |
exclusion criteria | 28 |
hev rna | 28 |
factors affecting | 28 |
coherent anti | 28 |
overall incidence | 28 |
patients transplanted | 28 |
previous reports | 28 |
post irradiation | 28 |
hiv patients | 28 |
selective inhibitors | 28 |
care services | 28 |
respiratory infections | 28 |
cellular protein | 28 |
among women | 28 |
nat testing | 28 |
mean time | 28 |
female patients | 28 |
situ hybridization | 28 |
studies revealed | 28 |
different concentrations | 28 |
york city | 28 |
early diagnosis | 28 |
autoimmune disease | 28 |
subgenomic rna | 28 |
several viruses | 28 |
mhc i | 28 |
treatment group | 28 |
donor deferral | 28 |
automated blood | 28 |
online version | 28 |
ribavirin combination | 28 |
storage lesion | 28 |
pretransfusion testing | 28 |
portal vein | 28 |
fetal bovine | 28 |
lipid raft | 28 |
expression system | 28 |
highly expressed | 28 |
allele frequencies | 28 |
cancer cell | 28 |
community pharmacies | 28 |
organ failure | 28 |
coronary artery | 28 |
sustained response | 28 |
dna vaccine | 28 |
pharmaceutical interventions | 28 |
per rbc | 28 |
stokes raman | 28 |
frequently used | 28 |
also occur | 28 |
plasma volume | 28 |
low density | 28 |
medical school | 28 |
laboratory findings | 28 |
emerging infectious | 28 |
east respiratory | 28 |
gradient centrifugation | 28 |
rare donor | 28 |
health system | 28 |
delivery system | 28 |
mice deficient | 28 |
wbc count | 28 |
virus replicon | 28 |
transfusion chain | 28 |
using pcr | 28 |
density gradient | 28 |
newly discovered | 28 |
adhesion molecules | 28 |
infection induces | 28 |
evidence indicates | 28 |
high doses | 28 |
roche cobas | 28 |
survival benefit | 28 |
usually associated | 28 |
transfusion policy | 28 |
consensus sequence | 28 |
side effect | 28 |
different methods | 28 |
tm domain | 28 |
inhibit viral | 28 |
nucleoside analogue | 28 |
ccr antagonists | 28 |
hbsag positive | 28 |
protein interacts | 28 |
cellular rna | 28 |
health centre | 28 |
deceased donor | 28 |
mayo clinic | 28 |
hcc cell | 28 |
diabetic patients | 28 |
nucleotide sequences | 28 |
immune activation | 28 |
hiv protease | 28 |
induced cell | 28 |
seroconversion panels | 28 |
saharan africa | 28 |
urgently needed | 28 |
full length | 28 |
rhd typing | 28 |
related liver | 28 |
many studies | 28 |
mouse cells | 28 |
isothermal amplification | 28 |
interacting protein | 27 |
donor liver | 27 |
recipient age | 27 |
heart transplantation | 27 |
hemoglobin level | 27 |
possible role | 27 |
autoimmune hemolytic | 27 |
seasonal influenza | 27 |
viral assembly | 27 |
potential antiviral | 27 |
total blood | 27 |
clinical presentation | 27 |
hcv may | 27 |
receptor signaling | 27 |
alt normalization | 27 |
side chain | 27 |
viral population | 27 |
acid sites | 27 |
viral glycoproteins | 27 |
single unit | 27 |
genotype hcv | 27 |
ethics committee | 27 |
infected liver | 27 |
plasma transfusion | 27 |
healthcare system | 27 |
plasma derivates | 27 |
antibody levels | 27 |
protein folding | 27 |
human rhinovirus | 27 |
expression profiling | 27 |
sp cells | 27 |
remains unknown | 27 |
immune status | 27 |
lateral flow | 27 |
health problems | 27 |
cobas amplicor | 27 |
regression model | 27 |
colistin resistance | 27 |
cell free | 27 |
fed infants | 27 |
cytokine secretion | 27 |
ns ns | 27 |
kupffer cells | 27 |
allograft recipients | 27 |
pegylated ifn | 27 |
samples showed | 27 |
following treatment | 27 |
found positive | 27 |
drug target | 27 |
cellular functions | 27 |
people worldwide | 27 |
tissue damage | 27 |
antimicrobial agents | 27 |
highly pathogenic | 27 |
genome sequences | 27 |
last two | 27 |
extracellular matrix | 27 |
human monocytes | 27 |
coronavirus infection | 27 |
resistant mutant | 27 |
kidney recipients | 27 |
surgery patients | 27 |
functional genomics | 27 |
compatibility testing | 27 |
higher rate | 27 |
virus strain | 27 |
will lead | 27 |
female patient | 27 |
hemoglobin levels | 27 |
positive impact | 27 |
epithelial cell | 27 |
every months | 27 |
derived cells | 27 |
transforming growth | 27 |
kinase inhibitors | 27 |
important roles | 27 |
patient outcomes | 27 |
related adverse | 27 |
treated group | 27 |
ehv vaccine | 27 |
automated system | 27 |
medical microbiology | 27 |
host antiviral | 27 |
neutralizing antibody | 27 |
many years | 27 |
liver samples | 27 |
novel therapeutic | 27 |
drug abuse | 27 |
assay kit | 27 |
different viral | 27 |
coagulation factor | 27 |
rna level | 27 |
derived dendritic | 27 |
translation inhibition | 27 |
cells express | 27 |
platelet activation | 27 |
liquid chromatography | 27 |
test compounds | 27 |
specific responses | 27 |
data showed | 27 |
virus rnas | 27 |
humoral immune | 27 |
healthy blood | 27 |
synergistic effect | 27 |
extracellular loop | 27 |
expression profiles | 27 |
disease caused | 27 |
rhd exons | 27 |
lyme disease | 26 |
membrane rearrangements | 26 |
cost effective | 26 |
natural products | 26 |
will require | 26 |
high proportion | 26 |
irradiated blood | 26 |
saccharomyces cerevisiae | 26 |
clinical specimens | 26 |
positive predictive | 26 |
confer resistance | 26 |
activated cd | 26 |
component therapy | 26 |
still unclear | 26 |
adaptive mutations | 26 |
jak stat | 26 |
rheumatoid arthritis | 26 |
gene promoter | 26 |
transfusion testing | 26 |
vasovagal reactions | 26 |
healthcare personnel | 26 |
murine model | 26 |
tight junction | 26 |
blood establishment | 26 |
stat pathway | 26 |
virus infectivity | 26 |
chronic inflammation | 26 |
study using | 26 |
studies indicate | 26 |
effective antiviral | 26 |
calculated using | 26 |
binding pocket | 26 |
large volume | 26 |
virus load | 26 |
study revealed | 26 |
nafld patients | 26 |
routine testing | 26 |
papillomavirus type | 26 |
community health | 26 |
raft cultures | 26 |
umbilical cord | 26 |
street youth | 26 |
virus vaccine | 26 |
molecular typing | 26 |
supplementary table | 26 |
rna extraction | 26 |
medication review | 26 |
protein inhibits | 26 |
viral nucleic | 26 |
high mortality | 26 |
late endosomes | 26 |
dna sequences | 26 |
sialic acid | 26 |
national institutes | 26 |
research center | 26 |
large scale | 26 |
days prior | 26 |
mononuclear cell | 26 |
splice site | 26 |
immunosuppressive drugs | 26 |
like protease | 26 |
newly emerging | 26 |
tyrosine phosphorylation | 26 |
speci fi | 26 |
maternal plasma | 26 |
spectra optia | 26 |
pcr testing | 26 |
considered significant | 26 |
previously identified | 26 |
mic mg | 26 |
tyrosine kinases | 26 |
inner city | 26 |
median follow | 26 |
care workers | 26 |
enveloped virus | 26 |
associated proteins | 26 |
potent inhibitors | 26 |
molecules per | 26 |
mediated endocytosis | 26 |
severe side | 26 |
intercept blood | 26 |
san francisco | 26 |
islet allograft | 26 |
antibody test | 26 |
immune cell | 26 |
cell separators | 26 |
one single | 26 |
hcv virus | 26 |
gel column | 26 |
van der | 26 |
severe cases | 26 |
vaccine design | 26 |
health outcomes | 26 |
gb virus | 26 |
pancreatic cancer | 26 |
compared using | 26 |
platelet additive | 26 |
laboratory data | 26 |
sequence alignment | 26 |
old man | 26 |
i signaling | 25 |
social support | 25 |
high expression | 25 |
hcv structural | 25 |
virus protein | 25 |
coding sequences | 25 |
membrane potential | 25 |
low viral | 25 |
surface proteins | 25 |
iron overload | 25 |
replication factories | 25 |
binding affinity | 25 |
blood glucose | 25 |
group ab | 25 |
inhibitors targeting | 25 |
two main | 25 |
also inhibited | 25 |
hcv replicase | 25 |
cd antibodies | 25 |
infected huh | 25 |
common causes | 25 |
among pwid | 25 |
apheresis donors | 25 |
time consuming | 25 |
among persons | 25 |
tlr ligands | 25 |
virus induces | 25 |
strongly associated | 25 |
experimental conditions | 25 |
inhibitory peptide | 25 |
analysis demonstrated | 25 |
i expression | 25 |
low rate | 25 |
response element | 25 |
alt level | 25 |
higher frequency | 25 |
effective therapy | 25 |
serum igg | 25 |
standard deviations | 25 |
molecular patterns | 25 |
standard treatment | 25 |
life threatening | 25 |
regulatory cells | 25 |
interferon production | 25 |
lesser extent | 25 |
rna detection | 25 |
pathogenic viruses | 25 |
weeks gestation | 25 |
medium containing | 25 |
reporter virus | 25 |
fi cation | 25 |
bowel disease | 25 |
i i | 25 |
autophagy machinery | 25 |
using human | 25 |
cardiac allografts | 25 |
prv infection | 25 |
infection occurs | 25 |
sustained viral | 25 |
selective inhibitor | 25 |
new automated | 25 |
white cell | 25 |
th th | 25 |
expression vector | 25 |
following transfusion | 25 |
antibody production | 25 |
human coronaviruses | 25 |
without affecting | 25 |
rna template | 25 |
lipid composition | 25 |
hbsag negative | 25 |
cell homeostasis | 25 |
miu ml | 25 |
gel cards | 25 |
haemolytic anaemia | 25 |
carbon dioxide | 25 |
elongation factor | 25 |
rejection episodes | 25 |
membranous replication | 25 |
group compared | 25 |
patients will | 25 |
coronavirus replication | 25 |
marrow cells | 25 |
different genotypes | 25 |
positive test | 25 |
volume reduction | 25 |
hours later | 25 |
platelet content | 25 |
gene transcription | 25 |
liver tissues | 25 |
less severe | 25 |
virus particle | 25 |
virus attachment | 25 |
treatment option | 25 |
one day | 25 |
intravenous immunoglobulin | 25 |
liver enzymes | 25 |
structural basis | 25 |
based methods | 25 |
donor safety | 25 |
solid tumors | 25 |
efficient replication | 25 |
lymphotropic virus | 25 |
one sample | 25 |